Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.
AsedaSciences signed a commercial agreement with Clyde Biosciences to integrate the CellOPTIQ cardiotoxicity screen into its 3RnD platform. The deal adds a validated in vitro CiPA assay for chemical and drug safety assessment.
A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07588425 |
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer |
NOT_YET_RECRUITING | |
| NCT07572175 |
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity |
NOT_YET_RECRUITING | PHASE2 |
| NCT07528586 |
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy |
RECRUITING | NA |
| NCT07442578 |
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial |
ACTIVE_NOT_RECRUITING | NA |
| NCT07405385 |
Cardiotoxicity Assessment and Reduction Through Exercise in BREAST Cancer |
NOT_YET_RECRUITING | NA |
| NCT07382141 |
Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age |
RECRUITING | NA |
| NCT07267247 |
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer |
COMPLETED | |
| NCT07191730 |
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies |
RECRUITING | |
| NCT07158450 |
Novel On-body Evaluation of Cardiac Health for Oncology |
ENROLLING_BY_INVITATION | |
| NCT07157670 |
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. |
NOT_YET_RECRUITING |
